TransMedics Group, Inc. (TMDX)
NASDAQ: TMDX · Real-Time Price · USD
121.54
-0.27 (-0.22%)
May 16, 2025, 1:05 PM - Market open
TransMedics Group Revenue
TransMedics Group had revenue of $143.54M in the quarter ending March 31, 2025, with 48.21% growth. This brings the company's revenue in the last twelve months to $488.23M, up 64.43% year-over-year. In the year 2024, TransMedics Group had annual revenue of $441.54M with 82.74% growth.
Revenue (ttm)
$488.23M
Revenue Growth
+64.43%
P/S Ratio
8.35
Revenue / Employee
$670,641
Employees
728
Market Cap
4.11B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 441.54M | 199.92M | 82.74% |
Dec 31, 2023 | 241.62M | 148.16M | 158.53% |
Dec 31, 2022 | 93.46M | 63.20M | 208.83% |
Dec 31, 2021 | 30.26M | 4.62M | 18.03% |
Dec 31, 2020 | 25.64M | 2.04M | 8.62% |
Dec 28, 2019 | Pro | Pro | Pro |
Dec 29, 2018 | Pro | Pro | Pro |
Dec 30, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 30, 2006 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
TMDX News
- 1 day ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Shareholders to Reach Out - Accesswire
- 3 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TransMedics Group, Inc. (TMDX) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 5 days ago - TransMedics Group, Inc. (TMDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire
- 7 days ago - TransMedics: Exceptional Q1 Undermines The Short Narrative - Seeking Alpha
- 7 days ago - TransMedics Group, Inc. (TMDX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - TransMedics Reports First Quarter 2025 Financial Results - PRNewsWire
- 8 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TransMedics Group, Inc. (TMDX) and Encourages Investors to Learn More About the Investigation - Accesswire
- 10 days ago - TransMedics Group, Inc. (TMDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Accesswire